Why is weight management changing?
For a long time, managing weight felt like a solo battle against your own biology. We now know that your body has specific receptors, which are like tiny docking stations on your cells, that control how hungry you feel and how you burn energy. New research is focused on compounds that talk to these receptors to help the process along.
Scientists are moving away from just focusing on one pathway and are now looking at multi-receptor agonists. This is a fancy way of saying they are trying to flip multiple switches in your body at the same time to help with weight and metabolism.
The triple threat: Retatrutide
Retatrutide is currently a first-in-class triple agonist. This means it targets three different receptors at once: GLP-1, GIP, and glucagon. While GLP-1 and GIP are common targets you may have heard of, adding the glucagon receptor is intended to add thermogenesis, which is just a technical term for increasing how much energy your body spends.
In studies, this triple-action approach showed a mean weight loss of up to 28.3% at 80 weeks, and even reached 30.3% in a longer 104-week extension. However, it is important to know that this is still investigational. We do not have long-term data on what happens after people stop taking it, and it is not yet FDA-approved.
Taking a pill instead of a shot?
If you aren't a fan of needles, Orforglipron is a non-peptide compound that you can take as a daily pill. Unlike some other oral options, you do not have to worry about food or water restrictions when you take it. It works as a GLP-1 receptor agonist to help reduce appetite and support weight loss.
The FDA approved Orforglipron for weight loss on April 1, 2026, under the brand name Foundayo. Because it is newer, we have less long-term information on it compared to older injectable options. Scientists are still waiting for more details on how well the results last over time.
The metabolic anchor: Survodutide
Survodutide is what researchers call a dual agonist. It targets two receptors: GLP-1 and glucagon. By hitting both, it aims to suppress your appetite while also increasing how your liver processes fat.
In a Phase II study, which is a mid-stage clinical trial, participants saw up to 18.7% weight loss over 46 weeks. There was also evidence that it could help improve liver health. Scientists are still working on this one — turns out the human body is complicated. Who knew? We are currently waiting for Phase III results to see if these findings hold up in larger groups of people.
How to learn more
Every body reacts differently to these options, and what works for one person might not be right for you. This is a great one to bring up with your doctor. You can find peptide-experienced physicians in our Find a Doctor directory.
Working with a qualified peptide doctor can help you understand the latest evidence and which options are currently FDA-approved or still in testing.
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.